Neurocrine Biosciences Inc (NBIX)

Net profit margin

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Net income (ttm)	US$ in thousands	341,300	385,900	339,200	369,700	249,700	191,000	176,400	64,000	154,500	58,200	12,200	71,400	89,600	444,800	364,700	402,000	407,300	93,400	204,800	176,500
Revenue (ttm)	US$ in thousands	2,355,300	2,241,400	2,117,000	1,978,200	1,882,900	1,779,300	1,668,300	1,522,900	1,411,600	1,306,100	1,208,800	1,185,500	1,107,700	1,050,200	1,010,800	1,022,200	1,020,900	1,017,010	981,066	862,604
Net profit margin		14.49%	17.22%	16.02%	18.69%	13.26%	10.73%	10.57%	4.20%	10.95%	4.46%	1.01%	6.02%	8.09%	42.35%	36.08%	39.33%	39.90%	9.18%	20.88%	20.46%

December 31, 2024 calculation

Net profit margin = Net income (ttm) ÷ Revenue (ttm)
= $341,300K ÷ $2,355,300K
= 14.49%

The net profit margin of Neurocrine Biosciences Inc has shown fluctuations over the past few years. The margin was strong in the first half of 2021, reaching over 35%, indicating that the company was efficiently managing its costs and generating healthy profits relative to its revenue during that period. However, there was a significant drop in profitability in the latter part of 2021 and early 2022, with the net profit margin falling below 10%.

Although there was a slight improvement in the net profit margin in the first half of 2023, it remained relatively low compared to previous periods. The margin showed a notable recovery towards the end of 2023 and continued to increase in 2024, reaching around 17%. This recovery suggests that Neurocrine Biosciences Inc may have implemented cost-saving measures or improved its revenue generation strategies.

Overall, the trend in net profit margin indicates some level of variability in the company's profitability over the reviewed period, with periods of strong performance followed by declines. It would be important for stakeholders to closely monitor Neurocrine Biosciences Inc's financial performance and assess the effectiveness of its operational and strategic decisions to sustain profitability in the long term.